Asirvatham Adlyne Reena, Balachandran Karthik, Kannan Subramanian, Balasubramaniam Satish K, Mahadevan Shriraam
Department of Endocrinology, Diabetes and Metabolism, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
Department of Endocrinology, Mazumdar Shaw Medical Centre, Narayana Health, Bengaluru, Karnataka, India.
Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):757-759. doi: 10.4103/ijem.IJEM_412_18.
Fracture Risk Assessment Tool (FRAX) is a fracture prediction tool that uses clinical risk factors with or without bone mineral density (BMD). BMD is difficult to obtain in resource-limited setting. Hence, we aimed to compare fracture risk prediction by FRAX without BMD (FRAX) and FRAX with BMD (FRAX/BMD).
We intended to determine if FRAX and FRAX/BMD would produce identical predictions for 10-year probability of hip fracture and major osteoporotic fracture (MOF). We also desired to study the risk factors that could help to identify the similarity of risk prediction.
A retrospective review of patients who underwent BMD measurement and FRAX assessment was conducted. Men and women >50 years of age with osteopenia and osteoporosis according to the World Health Organization (WHO) definition at one or more sites were included. FRAX prediction scores were calculated with and without BMD using the FRAX India tool.
Of 239 subjects, 207 (86.61%) had identical fracture risk predictions with or without BMD in FRAX estimation. Mean age was lower ( = 0.009), whereas body mass index (BMI), hip BMD, spine BMD, and history of previous fracture were higher ( = 0.005, < 0.001, < 0.001, and = 0.02, respectively) in the identical prediction group.
In our study, FRAX provided fracture risk prediction alike FRAX/BMD in most of the cases. FRAX is a good predictor of fractures especially in younger patients with higher BMI. Therefore, we conclude that FRAX is an effective tool to predict osteoporotic fracture risk and would be an inexpensive alternative when access to dual-energy X-ray absorptiometry (DXA) is limited.
骨折风险评估工具(FRAX)是一种骨折预测工具,可使用临床风险因素,无论是否结合骨密度(BMD)。在资源有限的环境中,骨密度难以获取。因此,我们旨在比较不使用骨密度的FRAX(FRAX)和使用骨密度的FRAX(FRAX/BMD)对骨折风险的预测。
我们旨在确定FRAX和FRAX/BMD对10年髋部骨折和主要骨质疏松性骨折(MOF)概率的预测是否相同。我们还希望研究有助于识别风险预测相似性的风险因素。
对接受骨密度测量和FRAX评估的患者进行回顾性研究。纳入年龄大于50岁、根据世界卫生组织(WHO)定义在一个或多个部位存在骨质减少和骨质疏松的男性和女性。使用FRAX印度工具计算有无骨密度时的FRAX预测分数。
在239名受试者中,207名(86.61%)在FRAX评估中有无骨密度时的骨折风险预测相同。在相同预测组中,平均年龄较低(=0.009),而体重指数(BMI)、髋部骨密度、脊柱骨密度和既往骨折史较高(分别为=0.005、<0.001、<0.001和=0.02)。
在我们的研究中,FRAX在大多数情况下提供的骨折风险预测与FRAX/BMD相似。FRAX是骨折的良好预测指标,尤其是在BMI较高的年轻患者中。因此,我们得出结论,FRAX是预测骨质疏松性骨折风险的有效工具,在双能X线吸收法(DXA)获取受限的情况下,它将是一种经济实惠的替代方法。